Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,427 full-time employees. The company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others.
Comment le bénéfice par action récent de IART se compare-t-il aux attentes ?
Le bénéfice par action le plus récent de Integra Lifesciences Holdings Corp est de $, les attentes de $0.41.
Comment les revenus de Integra Lifesciences Holdings Corp IART se sont-ils comportés au dernier trimestre ?
Les revenus de Integra Lifesciences Holdings Corp pour le dernier trimestre s'élèvent à $
Quelle est l'estimation des revenus pour Integra Lifesciences Holdings Corp ?
Selon 11 analystes de Wall Street, l'estimation des revenus de Integra Lifesciences Holdings Corp varie de $449.51M à $414.54M
Quel est le score de qualité des bénéfices pour Integra Lifesciences Holdings Corp ?
Integra Lifesciences Holdings Corp a un score de qualité des bénéfices de B+/57.435146. Le score est basé sur quatre dimensions : rentabilité, croissance, génération de trésorerie et allocation de capital, et effet de levier.
Quand Integra Lifesciences Holdings Corp publie-t-elle ses résultats ?
Le prochain rapport de résultats de Integra Lifesciences Holdings Corp est attendu pour 2026-08-03
Quels sont les bénéfices attendus de Integra Lifesciences Holdings Corp ?
Les bénéfices attendus de Integra Lifesciences Holdings Corp s'élèvent à $389.5M, selon les analystes de Wall Street.
Integra Lifesciences Holdings Corp a-t-elle dépassé les attentes en matière de bénéfices ?
Les bénéfices récents de Integra Lifesciences Holdings Corp s'élèvent à $, les attentes.